← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Other antineoplastic agents
omacetaxine mepesuccinate
L01XX40
Forms & Strengths
- Powder for injection: 3.5 mg per vial
Adult Dosing
- Induction: 1.25 mg/m² subcutaneously twice daily for 14 consecutive days every 28 days
- Maintenance: 1.25 mg/m² subcutaneously twice daily for 7 consecutive days every 28 days
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of adult patients with chronic myeloid leukemia (CML) with resistance or intolerance to two or more tyrosine kinase inhibitors (TKIs)
Mechanism of Action
- Protein translation inhibitor
- Directly binds to the A-site of the ribosome, inhibiting peptide bond formation
- Causes non-kinase-dependent downregulation of myeloid cell leukemia 1 (Mcl-1) and other leukemia-associated proteins regardless of TKI resistance mutations
Contraindications
- History of severe hypersensitivity to omacetaxine mepesuccinate
Adverse Reactions
- Myelosuppression (thrombocytopenia, neutropenia, anemia)
- Nausea and diarrhea
- Fatigue and asthenia
- Injection site reactions
- Fever and infection
- Lymphopenia
Drug Interactions
- Myelosuppressive agents: Concurrent use may increase the risk of bone marrow suppression and severe infection
- Vaccines: Administration of live vaccines is contraindicated due to immunosuppression
Curated Content: Needs Vetting Before Put to Clinical Use